International Consensus on Use of Continuous Glucose Monitoring

Measurement of glycated hemoglobin (HbA ) has been the traditional method for assessing glycemic control. However, it does not reflect intra- and interday glycemic excursions that may lead to acute events (such as hypoglycemia) or postprandial hyperglycemia, which have been linked to both microvascu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes care Jg. 40; H. 12; S. 1631
Hauptverfasser:	Danne, Thomas, Nimri, Revital, Battelino, Tadej, Bergenstal, Richard M, Close, Kelly L, DeVries, J Hans, Garg, Satish, Heinemann, Lutz, Hirsch, Irl, Amiel, Stephanie A, Beck, Roy, Bosi, Emanuele, Buckingham, Bruce, Cobelli, Claudio, Dassau, Eyal, Doyle, 3rd, Francis J, Heller, Simon, Hovorka, Roman, Jia, Weiping, Jones, Tim, Kordonouri, Olga, Kovatchev, Boris, Kowalski, Aaron, Laffel, Lori, Maahs, David, Murphy, Helen R, Nørgaard, Kirsten, Parkin, Christopher G, Renard, Eric, Saboo, Banshi, Scharf, Mauro, Tamborlane, William V, Weinzimer, Stuart A, Phillip, Moshe
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.12.2017
Schlagworte:	Blood Glucose - metabolism Blood Glucose Self-Monitoring - standards Clinical Trials as Topic Consensus Diabetes Mellitus, Type 1 - blood Diabetes Mellitus, Type 1 - drug therapy Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Glycated Hemoglobin - metabolism Humans Hyperglycemia - blood Hyperglycemia - drug therapy Hypoglycemia - blood Hypoglycemia - drug therapy Hypoglycemic Agents - therapeutic use Insulin - therapeutic use International Agencies Physicians Reference Standards Research Personnel
ISSN:	1935-5548, 1935-5548
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Measurement of glycated hemoglobin (HbA ) has been the traditional method for assessing glycemic control. However, it does not reflect intra- and interday glycemic excursions that may lead to acute events (such as hypoglycemia) or postprandial hyperglycemia, which have been linked to both microvascular and macrovascular complications. Continuous glucose monitoring (CGM), either from real-time use (rtCGM) or intermittently viewed (iCGM), addresses many of the limitations inherent in HbA testing and self-monitoring of blood glucose. Although both provide the means to move beyond the HbA measurement as the sole marker of glycemic control, standardized metrics for analyzing CGM data are lacking. Moreover, clear criteria for matching people with diabetes to the most appropriate glucose monitoring methodologies, as well as standardized advice about how best to use the new information they provide, have yet to be established. In February 2017, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address these issues. This article summarizes the ATTD consensus recommendations and represents the current understanding of how CGM results can affect outcomes.
Bibliographie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	1935-5548 1935-5548
DOI:	10.2337/dc17-1600